New data from two leading clinical studies show Lucentis is first therapy to improve vision in patients with wet age-related macular degeneration (AMD). AMD is leading cause of blindness for people over age 50.
Novartis announced today additional positive one-year data from two key clinical studies, MARINA and FOCUS, of the investigational new drug Lucentis (ranibizumab). Both studies successfully reached their primary endpoints and reported unprecedented results in maintaining and/or improving vision for patients with wet age-related macular degeneration (AMD). The trial results were presented today at the 23rd Annual Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada.
“We are delighted that these results show an improvement in vision, which is a significant breakthrough for AMD therapy and an important clinical outcome for physicians and the patients who suffer from this devastating disease,” said Flemming ?rnskov, M.D., President, Novartis Ophthalmics Business Unit.